Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMBITION: First-Line Combination in PAH
NCT01178073Phase 3Completed
- Sponsor
- GSK
- Start
- Oct 2010
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 3 trial of ambrisentan, tadalafil in pulmonary arterial hypertension (PAH), sponsored by GSK. Started Oct 2010; status: completed.
02
Drugs
ambrisentantadalafil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT01178073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01178073.